<DOC>
	<DOCNO>NCT02910752</DOCNO>
	<brief_summary>For acute leukemia patient early relapse allogeneic stem cell transplantation , overall outcome poor . In study , evaluate treatment outcome safety chemotherapy Cladribine , cytarabine mitoxantrone follow peripheral stem cell support original donor .</brief_summary>
	<brief_title>CLAM Chemotherapy With PBSC Support Relapsed Patients After Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>For acute leukemia patient experience relapse 6 month less allogeneic stem cell transplantation , overall outcome poor . In study , design treatment protocol aim achieve complete remission high-risk group patient chemotherapy consist Cladribine ( 5mg/m2 ) , cytarabine ( 1.5g/m2 ) mitoxantrone （10mg/m2）for 5 day follow infusion mobilize peripheral stem cell original donor . For patient fail achieved remission , second cycle give . For patient achieve remission , post-remission therapy open depend patient 's intent : consolidation one cycle , second allo-HSCT different donor continuous DLI .</detailed_description>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>patient acute leukemia relapse within 6 month previous alloHSCT active GVHD mobilize PBSC original donor available ECOG &gt; =3 liver function/renal function damage ( 2 X upper normal range ) active infection include CMV EBV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>